GSK plc announced on July 24, 2025, that Blenrep was approved in the EU for treating relapsed/refractory multiple myeloma, demonstrating significant benefits over existing therapies. The approval is based on trials showing nearly tripled median progression-free survival (PFS) of 36.6 months versus 13.4 months for the standard treatment.